Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 23, 2020
Daily News
March 23, 2020
- JPMA Chief Fires Back at Health Policy Advisor’s “Plenty of Financial Strength” Comment
March 23, 2020
- Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official
March 23, 2020
- Japan’s First Ophthalmology Regenerative Medicine Product Approved: J-TEC
March 23, 2020
- Japan Eases 30-Day Inspection Rules to Expedite Coronavirus Trials
March 23, 2020
- JPMA Members Increasing Drug Stockpiles to Deal with COVID-19, Need Govt Support: Chief
March 23, 2020
- Kitasato Institute Embarks on Drug Screening Project for COVID-19
March 23, 2020
- Oncolys to Create US Non-Clinical Research Subsidiary, Accelerating Drug R&D
March 23, 2020
- Eiken’s Novel Coronavirus Detection Reagent Kit Bags Public Insurance Coverage
March 23, 2020
- Asahi Kasei Grabs Global Rights for SBI Biotech’s Autoimmune Disease Therapy
March 23, 2020
- Fujifilm to Scale Up Production Capacity at UK Subsidiary with 9 Billion Yen Investment
March 23, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…